In our discussion of PB-1046 Phasebio's whose half life is 60 hours...WOW that's a lot longer. Totally tosses my theory out teh window and you are correct
And FURTHER the reason they eliminated the VPAC1 effect is because VPAC1 effect causes side effects such as diarrhea which if left unchecked would severely dehydrate a patient. BUT Since VPAC2 Effect is to lower BP, that is why they can administer that for 60 hours on a half life. Biochemistry is Freaking Amazing
So your counter to my mediocre anatomy knowledge is absolutely correct. That said I did look up long term effects on drug delivery with SUB Q admin and it's a highly interesting topic.
Knowing more about this I do have to wonder about PhaseBIO's clinical team. Not having known enough about the drug before writing earlier (A Very bad mistake on my part I apologize) After just reading a few things I have to wonder WHY they even went into Clinical trial, knowing that VPAC 1 was inhibited. The cost of Setting up a CT is prohibitive unless your MOA is clearly understood and thought to bring about efficacious results. By the time first submission of the study
May 28, 2020 we already knew the Virus affected the Aveloar Type II cells in the lungs as method of entry as written up in this May 6th abstract
Perhaps this is why the lackluster results of the trial led the company to abandon it like a hot rock held in a hand. I wonder if the research teams had voiced objections at all in internal documents
Market Data 
Markets 
AI
